NexTel Medical Amends Acquisition to Buy Island 40 Group for $12.75M, Expanding Platform
MAJI has more than doubled off its 52-week low of $0.002.
Summary
NexTel Medical amended its previously announced acquisition to buy Island 40 Group and its full subsidiary platform for $12.75 million, consisting of $3.5 million in cash and $9.25 million in preferred stock. The revised deal significantly expands the original scope, adding health services, pharmaceutical access, lab testing, and institutional partnerships to NexTel's exosome-based delivery pipeline. Island 40 Group currently serves over 300,000 patients per month across its channels, providing immediate commercial scale. The transaction is subject to customary closing conditions, including due diligence. For a micro-cap company with a market cap under $1 million, this acquisition represents a transformative shift from clinical-stage biotech to a diversified healthcare platform with existing revenue streams.
At the time of this announcement, MAJI was trading at $0.01 on OTC in the Life Sciences sector, with a market capitalization of approximately $713.9K. The 52-week trading range was $0.00 to $0.21. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.